Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions
University Hospital, Bordeaux
10 participants
Apr 10, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to perform an in-depth analysis of the molecular pathways involved in lesions responding to current treatment and lesions not responding to current treatment
Eligibility
Inclusion Criteria9
- Subject: male or female aged ≥ 18 years and ≤ 65 years
- Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet, with lesions located on arms
- Active non-segmental vitiligo is defined by:
- Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND
- Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination.
- Able to read, understand, and give documented informed consent
- Registered in the French Social Security
- Patients that could receive the combination of oral steroids and phototherapy according the recommendation
- Signed informed consent form
Exclusion Criteria3
- Segmental or mixed vitiligo
- Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures.
- Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq).
Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
narrowband UVB (Nb-UVB) 2 times a week
Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05927272